Descripción del proyecto
Diagnóstico más rápido de la resistencia a los antimicrobianos
El uso imprudente de antibióticos ha conllevado la aparición de resistencia a los antimicrobianos (RAM), provocada por bacterias que no pueden ser eliminadas por los fármacos existentes. La RAM amenaza los procedimientos hospitalarios establecidos y causa un número significativo de muertes cada año. El objetivo del proyecto Nanosynex, financiado con fondos europeos, es desarrollar una tecnología microfluídica revolucionaria que reduzca de forma notable el tiempo de procesamiento de las muestras y que ofrezca un diagnóstico más rápido de la RAM. La introducción del dispositivo en la práctica diagnóstica habitual ayudará a los médicos a tomar decisiones más fundamentadas y precisas sobre la administración de tratamientos antibióticos en sus pacientes.
Objetivo
Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR.
Inappropriate antibiotic use is widespread. In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long. Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours). This will allow physicians to get same-day results (i.e. in less than 5 hours) for AST, a unique feature that will save at least one day of hospitalization per patient and help reducing the spread of resistant bacteria. A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction. Nanosynex Ltd is an Israeli start-up providing health-care systems with a rapid microfluidic diagnostic solution for faster and personalised antibiotic treatment. The company intends to scale up in the European market first, thanks to its strategic partnership with Biosynex, a leading French rapid diagnostic test (RDT) company that has an established distribution network in Europe, Middle East and Africa (60+ countries). Afterwards, Nanosynex will expand internationally. Nanosynex forecast to generates 14.7M€ , and and at EBITDA of 3.4M€ by 2024
Ámbito científico
- natural sciencesbiological sciencesmicrobiologybacteriology
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- engineering and technologymedical engineeringmedical laboratory technologydiagnostic technologies
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
5126112 Bnei Brak
Israel
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.